Karl Hostetler

Prof. Karl Hostetler


Research Focus & Metrics

Academic Career Length

60Years (1967-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

3 March 1993 in European Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
MSMichael Schlame
Michael Schlame
SBStuart Brody
Stuart Brody
KHKarl Hostetler
Karl Hostetler

1 April 2002 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
EKEarl Kern
Earl Kern
CHCaroll Hartline
Caroll Hartline
EHEmma Harden
Emma Harden
KKKathy Keith
Kathy Keith
NRNatalie Rodriguez
Natalie Rodriguez
KHKarl Hostetler
Karl Hostetler
The nucleotide phosphonates cidofovir (CDV) and cyclic cidofovir (cCDV) are potent antiviral compounds when administered parenterally but are not well absorbed orally. These compounds have been reported to have activity against orthopoxvirus replication in vitro and in animal models when administered parenterally or by aerosol. To obtain better oral activity, we synthesized a novel series of analogs of CDV and cCDV by esterification with two long-chain alkoxyalkanols, 3-hexadecyloxy-1-propanol (HDP-CDV; HDP-cCDV) or 3-octadecyloxy-1-ethanol (ODE-CDV; ODE-cCDV). Their activities were evaluated and compared with those of CDV and cCDV in human foreskin fibroblast (HFF) cells infected with vaccinia virus (VV) or cowpox virus (CV) using a plaque reduction assay. The 50% effective concentrations (EC 50 s) against VV in HFF cells for CDV and cCDV were 46.2 and 50.6 μM compared with 0.84 and 3.8 μM for HDP-CDV and HDP-cCDV, respectively. The EC 50 s for ODE-CDV and ODE-cCDV were 0.20 and 1.1 μM, respectively. The HDP analogs were 57- and 13-fold more active than the parent nucleotides, whereas the ODE analogs were 231- and 46-fold more active than the unmodified CDV and cCDV. Similar results were obtained using CV. Cytotoxicity studies indicated that although the analogs were more toxic than the parent nucleotides, the selective index was increased by 4- to 13-fold. These results indicate that the alkoxyalkyl esters of CDV and cCDV have enhanced activity in vitro and need to be evaluated for their oral absorption and efficacy in animal models.

1 August 2003 in Antiviral Research
Verified
Journal Article
Closed access
SCStephanie L Ciesla
Stephanie L Ciesla
JTJulissa Trahan
Julissa Trahan
WWW.BRad Wan
W.BRad Wan
JBJames R Beadle
James R Beadle
KAKathy A Aldern
Kathy A Aldern
KHKarl Hostetler
Karl Hostetler

1 August 2005 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
WMWendy C. Magee
Wendy C. Magee
KHKarl Hostetler
Karl Hostetler
DEDavid Evans
David Evans
Cidofovir (CDV) is a broad-spectrum antiviral agent that has been approved for clinical use in the treatment of cytomegalovirus retinitis. It has also been used off label to treat a variety of other viral infections, including those caused by orf and molluscum contagiosum poxviruses. Because it is a dCMP analog, CDV is thought to act by inhibiting viral DNA polymerases. However, the details of the inhibitory mechanism are not well established and nothing is known about the mechanism by which the drug inhibits poxvirus DNA polymerases. To address this concern, we have studied the effect of the active intracellular metabolite of CDV, CDV diphosphate (CDVpp), on reactions catalyzed by vaccinia virus DNA polymerase. Using different primer-template pairs and purified vaccinia virus polymerase, we observed that CDV is incorporated into the growing DNA strand opposite template G's but the enzyme exhibits a lower catalytic efficiency compared with dCTP. CDV-terminated primers are also good substrates for the next deoxynucleoside monophosphate addition step, but these CDV + 1 reaction products are poor substrates for further rounds of synthesis. We also noted that although CDV can be excised from the primer 3′ terminus by the 3′-to-5′ proofreading exonuclease activity of vaccinia virus polymerase, DNAs bearing CDV as the penultimate 3′ residue are completely resistant to exonuclease attack. These results show that vaccinia virus DNA polymerase can use CDVpp as a dCTP analog, albeit one that slows the rate of primer extension. By inhibiting the activity of the proofreading exonuclease, the misincorporation of CDV could also promote error-prone DNA synthesis during poxvirus replication.

1 August 2002 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
JBJames R. Beadle
James R. Beadle
CHCaroll Hartline
Caroll Hartline
KAKathy A. Aldern
Kathy A. Aldern
NRNatalie Rodriguez
Natalie Rodriguez
EHEmma Harden
Emma Harden
KHKarl Hostetler
Karl Hostetler
The incidence of cytomegalovirus (CMV) retinitis is declining in AIDS patients but remains a significant clinical problem in patients with organ transplants and bone marrow transplants. Prophylaxis with ganciclovir (GCV) or valganciclovir reduces the incidence of CMV disease but may lead to the emergence of drug-resistant virus with mutations in the UL97 or UL54 gene. It would be useful to have other types of oral therapy for CMV disease. We synthesized hexadecyloxypropyl and octadecyloxyethyl derivatives of cyclic cidofovir (cCDV) and cidofovir (CDV) and found that these novel analogs had 2.5- to 4-log increases in antiviral activity against CMV compared to the activities of unmodified CDV and cCDV. Multiple-log increases in activity were noted against laboratory CMV strains and various CMV clinical isolates including GCV-resistant strains with mutations in the UL97 and UL54 genes. Preliminary cell studies suggest that the increase in antiviral activity may be partially explained by a much greater cell penetration of the novel analogs. 1- O -Hexadecyloxypropyl-CDV, 1- O -octadecyloxyethyl-CDV, and their corresponding cCDV analogs are worthy of further preclinical evaluation for treatment and prevention of CMV and herpes simplex virus infections in humans.